Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · Real-Time Price · USD
5.49
+0.31 (5.98%)
At close: Sep 26, 2025, 4:00 PM EDT
5.45
-0.04 (-0.73%)
After-hours: Sep 26, 2025, 7:33 PM EDT
Vir Biotechnology Employees
Vir Biotechnology had 408 employees as of December 31, 2024. The number of employees decreased by 179 or -30.49% compared to the previous year.
Employees
408
Change (1Y)
-179
Growth (1Y)
-30.49%
Revenue / Employee
$46,569
Profits / Employee
-$1,348,600
Market Cap
762.65M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
VIR News
- 11 days ago - Vir Biotechnology, Inc. (VIR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference - Business Wire
- 7 weeks ago - Vir Biotechnology, Inc. (VIR) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results - Business Wire
- 7 weeks ago - Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta - Business Wire
- 2 months ago - Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta - Business Wire
- 2 months ago - Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors - Business Wire
- 2 months ago - Vir Biotechnology: Hep B And Cancer Projects March On - Seeking Alpha